<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503736</url>
  </required_header>
  <id_info>
    <org_study_id>PNC00301</org_study_id>
    <nct_id>NCT01503736</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panion &amp; BF Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panion &amp; BF Biotech Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect and optimum dose and evaluate the safety
      of ferric citrate, administered three times daily (TID) immediately after meals for a total
      daily dose of 4 or 6 grams for 56 days, on serum phosphate (PO4) levels in subjects with end
      stage renal disease (ESRD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum phosphorus at Day 56 as compared to baseline</measure>
    <time_frame>Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphorus at Day 28 as compared to baseline</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ca x P product at Day 56 compared to baseline</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ca x P product at Day 28 compared to baseline</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative drop out rate due to serum phosphorus concentration &gt;9mg/dL at Day 56</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative drop out rate due to serum Phosphorus concentration &gt;9mg/dL at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric Citrate for a total daily dose of 4g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric Citrate for a total daily dose of 6g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric citrate</intervention_name>
    <description>0g/day ferric citrate capsule, TID for 56 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric citrate</intervention_name>
    <description>4g/day ferric citrate capsule, TID for 56 days</description>
    <arm_group_label>4g/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric citrate</intervention_name>
    <description>6 g/day ferric citrate capsule, TID for 56 days</description>
    <arm_group_label>6g/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years and has a diagnosis of ESRD

          -  On a three-times per week hemodialysis regimen

          -  On a stable dose of a phosphate-binding agent for at least one month prior to study
             entry.

          -  If on vitamin D supplementation or calcitriol, must be on a stable dose for at least
             one month prior to study entry.

          -  Hct &gt;= 20%

          -  Serum Ca level of 8 mg/dL to 10.5 mg/dL

        Exclusion Criteria:

          -  Is pregnant or lactating

          -  Clinically significant GI disorder

          -  Has tertiary hyperparathyroidism or is immediately post-operative from a
             parathyroidectomy (within the first 3 months post-op or the plasma Ca is &lt;7 mg/dL)

          -  ferritin&gt;800 ng/mL

          -  Unstable medical condition unsuitable for the study in the opinion of investigator

          -  Has been treated with an investigational agent within 30 days of enrollment

          -  Has a history of documented iron allergy or hemochromatosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Diseases</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Phosphorus Metabolism Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

